Loading...
Market
Will Colossal Biosciences revive the dodo by end of 2027?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Colossal Biosciences or reputable scientific publications
Story
Colossal Biosciences Raises $200M, Valued at $10.2B to Revive Woolly Mammoth, Dodo, and Tasmanian Tiger
Jan 15, 2025, 09:15 PM
Colossal Biosciences, a Dallas-based startup focused on de-extinction, has raised $200 million in a Series C funding round, bringing its valuation to $10.2 billion. The company, which aims to revive extinct species such as the woolly mammoth, dodo, and Tasmanian tiger, has now secured a total of $435 million in funding since its inception in 2021. The latest round was led by TWG Global, with Mark Walter and Thomas Tull at the helm. Colossal plans to use the new funds to expand its team, develop new technologies, and broaden its list of species targeted for de-extinction.
View original story
Similar markets
No • 50%
Yes • 50%
Dodo Bird • 25%
Other • 25%
Woolly Mammoth • 25%
Thylacine • 25%
Other • 25%
Tasmanian Tiger • 25%
Woolly Mammoth • 25%
Dodo Bird • 25%
Yes • 50%
No • 50%
Conservation International • 25%
WWF • 25%
The Nature Conservancy • 25%
Other • 25%
Above $15B • 25%
Below $5B • 25%
$5B to $10.2B • 25%
$10.2B to $15B • 25%
More than 3 new species • 25%
1 new species • 25%
2 new species • 25%
3 new species • 25%
